As stated in these first lines, the initial clinical success of anti-PD-1/PD-L1 antibodies was largely built on a simplified view of this pathway, primarily focusing on PD-L1 expression by tumor cells and its blockade to restore T-cell activity. Here, PDCD1 is linked to neoplasm.